Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. – Trademark Portfolio
Entity Type: 10
Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 7 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ADEQUAN. The owner is based in Munchen 70.
Zielstattstr. 9
Munchen 70 8000 , DE
Showing of trademarks Trademarks
Trademark Classifications
Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. have?
Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned, 4 cancelled.
What trademark classes does Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. file in?
Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co.'s most well-known trademarks?
Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co.'s registered trademark portfolio includes well-known marks such as ADEQUAN. These are among 1 currently registered trademark in the portfolio.
What is Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co.'s trademark registration success rate?
Luitpold-Werk Chemisch-Pharmazeutische Fabrik, GmbH & Co. has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.